Mimedx (MDXG) Net Income towards Common Stockholders (2011 - 2026)

Mimedx (MDXG) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at -$10.9 million (down 132.97% YoY), and the FY2025 full-year result was $48.6 million, up 15.67% from the prior year.
• Net Income towards Common Stockholders declined to -$10.9 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $44.8 million in Q4 2023 to a low of -$12.5 million in Q2 2022.
• A 4-year average of $4.6 million and a median of $7.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 681.83% in 2022, while the deepest fall reached 281.44% in 2022.
• Tracing MDXG's Net Income towards Common Stockholders over 4 years: stood at $8.1 million in 2022, then jumped by 451.13% to $44.8 million in 2023, then plunged by 83.41% to $7.4 million in 2024, then plunged by 246.01% to -$10.9 million in 2026.
• Business Quant data shows MDXG's Net Income towards Common Stockholders at -$10.9 million in Q1 2026, $7.4 million in Q4 2024, and $7.9 million in Q3 2024.